ArticleCell death & disease2025
A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The authors respond to feedback onFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC), the third-most prevalent and second deadliest cancer, requires new therapeutic strategies due to the significant side effects of current treatments. We investigated the anticancer properties of MakA, a cytotoxin from Vibrio cholerae, administered systemically in a mouse model, with a focus on its impact on the tumor microenvironment (TME) and immune cell infiltration. Our findings demonstrate that MakA administration is non-toxic and does not cause systemic tissue damage. It increases immune cell abundance in the TME, suppresses tumor growth, promotes cancer cell apoptosis, and enhances leukocyte recruitment and activation. Elevated neutrophil and macrophage densities were associated with increased production of pro-inflammatory mediators with anti-neoplastic properties. These findings highlight MakA's potential as a targeted, less harmful CRC therapy by modulating the TME immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.